No, the surgery was not necessarily unneeded—this is a well-recognized phenomenon in CIN management
The absence of dysplasia on final hysterectomy pathology does not mean the surgery was inappropriate, as this occurs in 15-25% of cases where CIN II was previously documented on biopsy. 1 This represents either complete excision of the lesion during prior procedures (like colposcopy biopsy or LEEP) or spontaneous regression between diagnosis and surgery.
Understanding Why No Dysplasia Was Found
The decision to perform hysterectomy was based on the pre-operative diagnosis of CIN II, which is the appropriate standard of care. Several factors explain the negative pathology:
- Prior biopsy may have completely removed the lesion: Colposcopy-guided biopsies can sometimes excise the entire dysplastic area, particularly if the lesion was small
- Spontaneous regression: CIN II can regress spontaneously, though this is less predictable than CIN I
- Sampling adequacy: The pre-operative biopsy accurately identified disease that was present at the time of diagnosis
Was the Decision Appropriate?
According to NCCN guidelines, hysterectomy for CIN II is acceptable when other indications for hysterectomy exist (such as symptomatic fibroids or persistent abnormal bleeding) 2. The guidelines explicitly state that hysterectomy is "another recommended option if the lesion is CIN III and if other indications for hysterectomy are present."
For CIN II specifically, the guidelines note that while treatment with LEEP, cryotherapy, or laser ablation is standard, hysterectomy can be considered if there are concurrent gynecologic indications 2.
Important Context About Treatment Timing
The key issue is not whether dysplasia was found in the final specimen, but rather:
- Was CIN II properly documented on pre-operative biopsy? If yes, the indication was valid
- Were there other gynecologic indications for hysterectomy? This makes the procedure more appropriate
- What was the time interval between diagnosis and surgery? Longer intervals allow more opportunity for regression
- Were less invasive options considered first? Guidelines suggest LEEP or cone biopsy as first-line for CIN II in most cases
The Overtreatment Concern
Recent data shows that 26.8% of hysterectomies performed for CIN show no pathology or only CIN I on final pathology, suggesting potential overtreatment 3. However, this must be balanced against the fact that:
- 1.24% of cases reveal occult invasive cancer that would have been missed without surgery 3
- Women with documented CIN II remain at risk and require intensive surveillance if not treated
- The decision was made based on the best available information at the time
What This Means Going Forward
You should continue with appropriate post-hysterectomy surveillance, as guidelines recommend:
- Women with a history of CIN II should continue screening even after hysterectomy with cervical removal 2
- Vaginal cytology should continue, as 5-19.6% of women develop vaginal intraepithelial neoplasia (VAIN) after hysterectomy for CIN 4, 5
- Annual screening is recommended for at least 20 years after treatment for high-grade CIN 2
The Bottom Line
The surgery was based on legitimate pre-operative findings of CIN II. The absence of dysplasia in the final specimen is a known outcome that occurs in 15-25% of cases and does not retroactively invalidate the indication. However, if hysterectomy was performed without other gynecologic indications and without first attempting conservative excisional procedures (LEEP or cone biopsy), this would represent a deviation from current guidelines, which favor fertility-sparing approaches as first-line treatment for CIN II 2, 6.